Manning & Napier Group's AZN Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 770,712 shares of AstraZeneca PLC (AZN) worth $142.6 M, representing 1.85% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Manning & Napier Group has maintained a strategic position in AZN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 1.03 M shares. Largest reduction occurred in Q2 2025, reducing 451,346 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -110,384 | Reduce 12.53% | 770,712 | $185.02 |
| Q3 2025 | -195,172 | Reduce 18.13% | 881,096 | $153.44 |
| Q2 2025 | -451,346 | Reduce 29.55% | 1.08 M | $139.76 |
| Q1 2025 | -345,152 | Reduce 18.43% | 1.53 M | $147.00 |
| Q4 2024 | +282,149 | Add 17.74% | 1.87 M | $131.04 |
| Q3 2024 | +382,281 | Add 31.64% | 1.59 M | $155.82 |
| Q2 2024 | -197,198 | Reduce 14.03% | 1.21 M | $155.98 |
| Q1 2024 | +15,929 | Add 1.15% | 1.41 M | $135.50 |
| Q4 2023 | +1.03 M | Add 281.16% | 1.39 M | $134.70 |
| Q3 2023 | +2,091 | Add 0.58% | 364,574 | $135.44 |
| Q2 2023 | +724,965 | New Buy | 362,483 | $143.14 |
| Q1 2017 | -247,980 | Sold Out | 0 | $0.00 |
| Q3 2016 | +4,095 | Add 1.68% | 247,980 | $65.71 |
| Q1 2016 | +13,965 | Add 6.07% | 243,885 | $56.32 |
| Q4 2015 | +2,050 | Add 0.90% | 229,920 | $67.89 |
| Q4 2014 | -89,310 | Reduce 28.16% | 227,870 | $70.37 |
| Q3 2014 | +8,150 | Add 2.64% | 317,180 | $71.44 |
| Q2 2014 | -150,539 | Reduce 32.76% | 309,030 | $74.31 |
| Q1 2014 | -31,309 | Reduce 6.38% | 459,569 | $64.88 |
| Q4 2013 | -18,067 | Reduce 3.55% | 490,878 | $59.37 |
| Q3 2013 | -2,722 | Reduce 0.53% | 508,945 | $51.93 |
| Q2 2013 | +511,667 | Add 0.00% | 511,667 | $47.30 |
Manning & Napier Group's AstraZeneca PLC Investment FAQs
Manning & Napier Group first purchased AstraZeneca PLC (AZN) in Q2 2013, acquiring 511,667 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held AstraZeneca PLC (AZN) for 27 quarters since Q2 2013.
Manning & Napier Group's largest addition to AstraZeneca PLC (AZN) was in Q4 2023, adding 1,389,606 shares worth $187.18 M.
According to the latest 13F filing for Q4 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 770,712 shares of AstraZeneca PLC (AZN), valued at approximately $142.6 M.
As of the Q4 2025 filing, AstraZeneca PLC (AZN) represents approximately 1.85% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in AstraZeneca PLC (AZN) was 1,872,766 shares, as reported at the end of Q4 2024.